[1] Ludman, A., Venugopal, V., Yellon, D., et al. (2009) Statins and Cardioprotection—More than Just Lipid Lowering? Pharmacology & Therapeutics, 122, 30-43.
http://dx.doi.org/10.1016/j.pharmthera.2009.01.002
[2] Hurst, M. (2008) Hurst Reviews, Pathophysiology Review. 1st Edition, McGraw-Hill, New York, 194-199.
[3] Torpy, J., Burke, A. and Glass, R. (2009) Coronary Heart Disease Risk Factors. JAMA, 302, 2388.
http://dx.doi.org/10.1001/jama.302.21.2388
[4] White, F. and Wang, L. (2006) Statins and Coronary Artery Disease. The Internet Journal of Cardiovascular Research, 3.
[5] Kapur, N. and Musunuru, K. (2008) Clinical Efficacy and Safety of Statins in Managing Cardiovascular Risk. Journal of Vascular Health and Risk Management, 2, 341-353.
[6] Bhardwaj, S. and Chalasani, N. (2007) Lipid Lowering Agents That Cause Drug-Induced Hepatotoxicity. Clinics in Liver Disease, 11, 597-613.
http://dx.doi.org/10.1016/j.cld.2007.06.010
[7] Golomb, B. and Evans, M. (2008) Statin Adverse Effects A Review of the Literature and Evidence for a Mitochondrial Mechanism. American Journal of Cardiovascular Drugs, 8, 373-418.
http://dx.doi.org/10.2165/0129784-200808060-00004
[8] Mckenney, J. (2003) Pharmacologic Characteristics of Statins. Clinical Cardiology, 26, 32-38.
http://dx.doi.org/10.1002/clc.4960261507
[9] Thadani1, U. (2009) Treatment with Statins in High-Risk Patients: Relevance of Time to Titration of Dose and Adverse Outcomes. American Journal of Cardiovascular Drugs, 3, 211-212.
[10] Chalasani, N. (2005). Statins and Hepatotoxicity: Focus on Patients with Fatty Liver. Hepatology, 41, 690-695.
http://dx.doi.org/10.1002/hep.20671
[11] Armitage, J. (2007) The Safety of Statins in Clinical Practice. Lancet, 370, 1781-1790.
http://dx.doi.org/10.1016/S0140-6736(07)60716-8
[12] Cohen, D., Anania, F. and Chalasani, N. (2006) An Assessment of Statin Safety by Hepatologists. American Journal of Cardiology, 97, S77-S81.
http://dx.doi.org/10.1016/j.amjcard.2005.12.014
[13] Deeg, R. and Ziegenhorn, J. (1983) Kinetic Enzymatic Method for Automated Determination of Total Cholesterol in Serum. Clinical Chemistry, 29, 1798-1802.
[14] Friedewald, W.T., Levy, R.I. and Fredrickson, D.S. (1972) Estimation of the Concentration of Low-Density Lipoprotein Cholesterol in Plasma, without Use of the Preparative Ultracentrifuge. Clinical Chemistry, 18, 499-502.
[15] Lopes-Virella, M., Stone, P., Ellis, S. and Colwell, J. (1977) High Density Lipoprotein and Low Density Lipoproteins. Clinical Chemistry, 23, 882.
[16] National Cholesterol Education Program (NCEP), Third Report (2002) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation, 106, 3143-3421.
[17] Calderon, R.M., Cubeddu, L.X., Goldberg, R.B. and Schiff, E.R. (2010) Statins in the Treatment of Dyslipidemia in the Presence of Elevated Liver Aminotransferase Levels: A Therapeutic Dilemma. Mayo Clinic Proceedings, 85, 349-356.
http://dx.doi.org/10.4065/mcp.2009.0365
[18] Fraser, A. (2002) Interpretation of Liver Enzyme Tests—A Rapid Guide. Zealand Family Physician Journal, 29, 117-120.
[19] Chang, C.Y. and Schiano, T.D. (2007) Review Article: Drug Hepatotoxicity. Alimentary Pharmacology & Therapeutics, 25, 1135-1151.
http://dx.doi.org/10.1111/j.1365-2036.2007.03307.x
[20] Al-Jubori, Z. and Mahmood, I. (2007) Comparative Effects of Lovastatin and Simvastatin on Liver Function Tests in Hyperlipdaemic Patients. The Medical Journal of Basrah University, 25, 19-24.
[21] Tolman, K. (2002) The Liver and Lovastatin. American Journal of Cardiology, 89, 1374-1380.
http://dx.doi.org/10.1016/S0002-9149(02)02355-X
[22] Buse, J. (2003) Statin Treatment in Diabetes Mellitus. Clinical Diabetes, 21, 168-172.
http://dx.doi.org/10.2337/diaclin.21.4.168
[23] Gotto, A.M. (2003) Safety and Statin Therapy: Reconsidering the Risk and Benefits. JAMA Internal Medicine, 163, 657-659.
http://dx.doi.org/10.1001/archinte.163.6.657
[24] Pelli, N., Setti, M., Cella, P., Toncini, C. and Indiveri, F. (2003) Autoimmune Hepatitis Revealed by Atorvastatin. European Journal of Gastroenterology & Hepatology, 15, 921-924.
[25] Castro, M., Hermo, J., Baz, A., Luaces, C., Perez, R. and Clofent, J. (2006) Acute Cholestatic Hepatitis after Atorvastatin Reintroduction. Gastroenterología y Hepatología, 29, 21-24.
[26] Angulo, P. (2002) Nonalcoholic Fatty Liver Disease. New England Journal of Medicine, 346, 1221-1231.
http://dx.doi.org/10.1056/NEJMra011775
[27] Bernini, F., Poli, A. and Paoletti, R. (2001) Safety of HMG-CoA Reductase Inhibitors: Focus on Atorvastatin. Cardiovascular Drugs and Therapy, 15, 211-218.
http://dx.doi.org/10.1023/A:1011908004965
[28] Wierzbicki, A., Lumb, P., Semra, Y. and Crook, M. (1998) Effect of Atorvastatin on Plasma Fibrinogen. Lancet, 351, 569-570.
http://dx.doi.org/10.1016/S0140-6736(05)78556-1
[29] Wierzbicki, A., Lumb, P. and Chik, G. (2001) Comparison of Therapy with Simvastatin 80 mg and 120 mg in Patients with Familial Hypercholesterolaemia. International Journal of Clinical Practice, 55, 673-675.
[30] Wierzbicki, A., Poston, R. and Ferro, A. (2003) The Lipid and Non-Lipid Effects of Statins. Pharmacology & Therapeutics, 99, 95-112.
http://dx.doi.org/10.1016/S0163-7258(03)00055-X
[31] Macdonald, J. and Halleck, M. (2004) The Toxicology of HMG-CoA Reductase Inhibitors: Prediction of Human Risk. Toxicologic Pathology, 32, 26-41.
http://dx.doi.org/10.1080/01926230490462057
[32] Minha, S., Golzman, G., Adar, I. and Rapoport, M. (2009) Cholestatic Jaundice Induced by Atorvastatin: A Possible Association with Antimitochondrial Antibodies. Israel Medical Association Journal, 11, 440-441.
[33] CDER-PH RMA, AASLD Conference (2000) Clinical White Paper on Drug-Induced Hepatotoxicity.
[34] Ahmed, A. and Cudmore, M. (2009) Can the Biology of VEGF and Haem Oxygenases Help Solve Pre-Eclampsia? Molecular and Cellular Mechanisms of Angiogenesis. Biochemical Society Transactions, 37, 1237-1242.
http://dx.doi.org/10.1042/BST0371237
[35] Wassmann, S., Laufs, U., Baumer, A., Muller, K., Ahlbory, K., Linz, W., et al. (2001) HMG-CoA Reductase Inhibitors Improve Endothelial Dysfunction in Normocholesterolemic Hypertension via Reduced Production of Reactive Oxygen Species. Hypertension, 37, 1450-1457.
http://dx.doi.org/10.1161/01.HYP.37.6.1450
[36] Wassmann, S., Laufs, U., Muller, K., Konkol, C., Ahlbory, K., Baumer, A., et al. (2002) Cellular Antioxidant Effects of Atorvastatin in Vitro and in Vivo. Arteriosclerosis, Thrombosis, and Vascular Biology, 22, 300-305.
http://dx.doi.org/10.1161/hq0202.104081
[37] Perez-Guerrero, C., De Sotomayor, M., Jimenez, L., Herrera, M. and Marhuenda, E. (2003) Effects of Simvuastatin on Endothelial Function after Chronic Inhibition of Nitric Oxide Synthase by L-NAME. Journal of Cardiovascular Pharmacology, 42, 204-210.
http://dx.doi.org/10.1097/00005344-200308000-00008
[38] Larrey, D. (2002) Epidemiology and Individual Susceptibility to Adverse Drug Reactions Affecting the Liver. Seminars in Liver Disease, 22, 145-155.
http://dx.doi.org/10.1055/s-2002-30101
[39] Sheth, S., Gordon, F. and Chopra, S. (1997) Nonalcoholic Steatohepatitis. Annals of Internal Medicine, 126, 137-145.
http://dx.doi.org/10.7326/0003-4819-126-2-199701150-00008
[40] Kiortsis, D., Nikas, S., Hatzidimou, K., Tsianos, E. and Elisaf, M.S. (2003) Lipid-Lowering Drugs and Serum Liver Enzymes: The Effects of Body Weight and Baseline Enzyme Levels. Fundamental & Clinical Pharmacology, 17, 491-494.
http://dx.doi.org/10.1046/j.1472-8206.2003.00176.x
[41] Shepherd, J., Cobb, S., Ford, I., et al. (1995) Fibrates and Statins in the Treatment of Hyperlipidemia: An Appraisal of Their Efficacy and Safety. European Journal of Cardiology, 16, 5-13.
[42] Ballantyne, C., Blazing, M., Hunninghake, D., Davidson, M.H., Yuan, Z., DeLucca, P., Ramsey, K.E., Hustad, C.M. and Palmisano, J. (2003) Effect on High-Density Lipoprotein Cholesterol of Maximum Dose Simvastatin and Atorvastatin in Patients with Hypercholesterolemia: Results of the Comparative HDL Efficacy and Safety Study (CHESS). American Heart Journal, 146, 862-869.
http://dx.doi.org/10.1016/S0002-8703(03)00440-X
[43] Illingworth, D., Crouse, J., Hunninghake, D., Davidson, M.H., Escobar, I.D., Stalenhoef, A.F., et al. (2001) A Comparison of Simvastatin and Atorvastatin up to Maximal Recommended Doses in a Large Multicenter Randomized Clinical Trial. Current Medical Research and Opinion, 17, 43-50.
[44] Shepherd, J., Blauw, G., Murphy, M., Bollen, E.L.E.M., Buckley, B.M., Cobbe, S.M., et al. (2002) Pravastatin in Elderly Individuals at Risk of Vascular Disease (PROSPER): A Randomized Controlled Trial. Lancet, 360, 1623-1630.
http://dx.doi.org/10.1016/S0140-6736(02)11600-X
[45] Law, M. and Rudnicka, A. (2006) Statin Safety: A Systematic Review. American Journal of Cardiology, 97, S52-S60.
http://dx.doi.org/10.1016/j.amjcard.2005.12.010
[46] Gladding, P., Pilmore, H. and Edwards, C. (2004) Potentially Fatal Interaction between Diltiazem and Statins. Annals of Internal Medicine, 140, W31.
[47] Onusko, E. (2008) Statins and Elevated Liver Tests: What’s the Fuss? Even When Liver Function Tests Are Moderately Elevated, Statins Are Safe for Most Patients. Journal of Family Practice, 57, 449-452.